CR20140516A - Compuestos de pirazol sustituidos como antagonistas de lpar - Google Patents

Compuestos de pirazol sustituidos como antagonistas de lpar

Info

Publication number
CR20140516A
CR20140516A CR20140516A CR20140516A CR20140516A CR 20140516 A CR20140516 A CR 20140516A CR 20140516 A CR20140516 A CR 20140516A CR 20140516 A CR20140516 A CR 20140516A CR 20140516 A CR20140516 A CR 20140516A
Authority
CR
Costa Rica
Prior art keywords
lpg
antagonist
compounds replaced
pirazol
pirazol compounds
Prior art date
Application number
CR20140516A
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140516(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20140516A publication Critical patent/CR20140516A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En este documento se proporcionan compuestos de la fórmula (I): así como sales farmacéuticamente aceptables de los mismos, donde los sustituyentes son aquellos divulgados en la memoria descriptiva. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades y trastornos inflamatorios, tales como, por ejemplo, fibrosis pulmonar.
CR20140516A 2012-06-20 2014-11-11 Compuestos de pirazol sustituidos como antagonistas de lpar CR20140516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
CR20140516A true CR20140516A (es) 2014-12-01

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140516A CR20140516A (es) 2012-06-20 2014-11-11 Compuestos de pirazol sustituidos como antagonistas de lpar

Country Status (22)

Country Link
US (1) US20150259295A1 (es)
EP (1) EP2864294A1 (es)
JP (1) JP2015520201A (es)
KR (1) KR20150011003A (es)
CN (1) CN104411690A (es)
AU (1) AU2013279510A1 (es)
BR (1) BR112014031108A2 (es)
CA (1) CA2869602A1 (es)
CL (1) CL2014003242A1 (es)
CO (1) CO7160077A2 (es)
CR (1) CR20140516A (es)
EA (1) EA201492283A1 (es)
HK (1) HK1206341A1 (es)
IL (1) IL236091A0 (es)
IN (1) IN2014DN09347A (es)
MA (1) MA37765A1 (es)
MX (1) MX2014014105A (es)
PE (1) PE20142445A1 (es)
PH (1) PH12014502364A1 (es)
SG (1) SG11201407229UA (es)
UA (1) UA109867C2 (es)
WO (1) WO2013189862A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
CA2953472C (en) 2014-06-27 2022-08-02 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
BR112020011953A2 (pt) * 2017-12-19 2020-11-17 Bristol-Myers Squibb Company ácidos carbamoil ciclo-hexílicos n-ligados a pirazol como antagonistas de lpa
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4337641A1 (en) * 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AU2022405082A1 (en) 2021-12-08 2024-07-11 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698335A4 (en) * 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
US9272990B2 (en) * 2010-12-07 2016-03-01 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013025733A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
MA37765A1 (fr) 2017-04-28
BR112014031108A2 (pt) 2017-06-27
CN104411690A (zh) 2015-03-11
CL2014003242A1 (es) 2015-03-20
HK1206341A1 (en) 2016-01-08
AU2013279510A1 (en) 2014-10-16
UA109867C2 (ru) 2015-10-12
KR20150011003A (ko) 2015-01-29
JP2015520201A (ja) 2015-07-16
MX2014014105A (es) 2015-03-05
US20150259295A1 (en) 2015-09-17
CO7160077A2 (es) 2015-01-15
EP2864294A1 (en) 2015-04-29
IN2014DN09347A (es) 2015-07-17
PH12014502364A1 (en) 2015-01-12
CA2869602A1 (en) 2013-12-27
EA201492283A1 (ru) 2015-04-30
IL236091A0 (en) 2015-02-01
SG11201407229UA (en) 2014-12-30
WO2013189862A1 (en) 2013-12-27
PE20142445A1 (es) 2015-01-28

Similar Documents

Publication Publication Date Title
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar
UY39630A (es) Inhibidores de bromodominios
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CL2017000089A1 (es) Espirocicloheptanos como inhibidores de rock
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
CU20150062A7 (es) Lactamas n-(heteroarilo sustituido) fusionadas utiles en el tratamiento del crecimiento celular anormal
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
UY34959A (es) Dihidropiridona p1 como inhibidores del factor xia
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
DOP2015000069A (es) Piridinonas bicíclicas novedosas
ECSP14013215A (es) Compuestos novedosos
UY36416A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2013011728A (es) Nuevos compuestos de benzofurano-piperidina.
CU20100210A7 (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CU20110002A7 (es) Derivados de triazol útiles para el tratamiento de enfermedades